Jeffrey A. Sosman
0000-0002-0650-9698
Publication & Citation Trends
Publications
0 total
A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab.
Cited by 2
Semantic Scholar
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. OA
Cited by 24
Semantic Scholar
Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. OA
Cited by 11
Semantic Scholar
Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).
Cited by 20
Semantic Scholar
Innovations and Challenges in Renal Cancer: Proceedings of the Third Cambridge Conference June 27‐28, 2008
Cited by 0
Semantic Scholar
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group
Cited by 150
Semantic Scholar
Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.
Cited by 34
Semantic Scholar
Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Cited by 16
Semantic Scholar
Research Topics
Melanoma and MAPK Pathways
(369)
Cancer Immunotherapy and Biomarkers
(297)
CAR-T cell therapy research
(199)
Cutaneous Melanoma Detection and Management
(173)
Immunotherapy and Immune Responses
(120)
Affiliations
Northwestern University
University of Southern California
Novartis (Switzerland)
Midwestern University
Dartmouth–Hitchcock Medical Center